Dr. Javier Ortiz Orendain, MD

Dr. Ortiz Orendain practices at University of New Mexico Hospital in Albuquerque, New Mexico, part of The University of New Mexico.

Dr. Ortiz Orendain's NPI, 1801381462, was assigned on June 26, 2018. Dr. Ortiz Orendain holds New Mexico license MD2022-1532.

Dr. Ortiz Orendain's primary practice is University of New Mexico Hospital, at 2211 Lomas Boulevard NE, Albuquerque, NM 87106 in Bernalillo County. The practice phone is (505) 272-2111.

Dr. Ortiz Orendain's primary practice is University of New Mexico Hospital in Albuquerque, New Mexico, part of The University of New Mexico. The medical group on file is UNM Medical Group, Inc. Dmand AI also links Dr. Ortiz Orendain to 1 more group practice or clinic and 1 medical group, each named with a free account. Dr. Ortiz Orendain's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ortiz Orendain practices, 2 sites in all. Vendor and product names are available with a free account.

Psychiatry is Dr. Ortiz Orendain's primary specialty in the NPI Registry, under taxonomy code 2084P0800X. Dr. Ortiz Orendain is licensed in New Mexico.

CMS data shows 77 Medicare services from Dr. Ortiz Orendain across 1 procedure code in 2024, all of them office visits, for 59 Medicare patients. Medicare paid $4,757 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 59 Medicare patients who saw Dr. Ortiz Orendain in 2024. The largest group is under 65, with 48 patients. 75% of them have schizophrenia and other psychoses, and 68% have mood disorders. Their average risk score is 1.28, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Ortiz Orendain's median patient age at 41, with 39% women.

In 2024, Dr. Ortiz Orendain wrote 784 Medicare Part D claims for 87 patients. 81% of them were for generic drugs. CMS names the drug for 631 of them, across 24 drugs with 11 or more claims each, at $236,848 in total drug cost. In 2023, CMS named 106 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Ortiz Orendain for performance year 2024, reported as part of a group. Dr. Ortiz Orendain accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 11 general payments to Dr. Ortiz Orendain from 3 drug and device companies from 2023 to 2024. Travel and lodging make up the largest share, 68% of the total. Boehringer Ingelheim Pharmaceuticals, Inc. paid the most, $1,220.